March 3, 2026Open Access

Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype

Key Points

Elevated ferritin levels correlate with disease activity in RNP/Sm-positive lupus patients, indicating a potential marker for severity.
Patients with RNP/Sm positivity show significant resistance to common treatments, often leading to flare-ups.
Analysis highlights the role of intermediate monocytes and their TLR4 upregulation in myeloid-driven inflammation.
Understanding ferritin as a companion biomarker may help target therapies more effectively in treatment-resistant lupus cases.

Abstract

Anti-RNP/Sm co-positivity defines a high-risk, flare-prone, myeloid-dominant SLE endotypeRNP⁺Sm⁺ patients, especially Black patients, show profound refractoriness to first-line and B-cell depletion therapiesExpanded intermediate monocytes with TLR4 upregulation and IFNA10-biased interferon signallingHyperferritinaemia correlates with disease activity exclusively in RNP⁺Sm⁺ patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Muhammad RA Shipa

Claire Beesley

Daniel McClusky

Actions

Institutions

University College London

University of California, San Francisco

University College Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study